Fjarde AP Fonden Fourth Swedish National Pension Fund Reduces Holdings in Insulet Co. (NASDAQ:PODD)

Fjarde AP Fonden Fourth Swedish National Pension Fund trimmed its holdings in shares of Insulet Co. (NASDAQ:PODD) by 28.0% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 11,300 shares of the medical instruments supplier’s stock after selling 4,400 shares during the period. Fjarde AP Fonden Fourth Swedish National Pension Fund’s holdings in Insulet were worth $2,950,000 as of its most recent SEC filing.

A number of other hedge funds have also modified their holdings of the business. Allianz Asset Management GmbH grew its stake in Insulet by 27.7% in the 4th quarter. Allianz Asset Management GmbH now owns 113,921 shares of the medical instruments supplier’s stock worth $29,741,000 after acquiring an additional 24,734 shares during the period. ING Groep NV purchased a new stake in Insulet in the 4th quarter worth approximately $556,000. Handelsbanken Fonder AB grew its stake in Insulet by 9.9% in the 4th quarter. Handelsbanken Fonder AB now owns 18,916 shares of the medical instruments supplier’s stock worth $4,938,000 after acquiring an additional 1,700 shares during the period. Private Advisor Group LLC grew its stake in Insulet by 30.5% in the 4th quarter. Private Advisor Group LLC now owns 9,642 shares of the medical instruments supplier’s stock worth $2,517,000 after acquiring an additional 2,255 shares during the period. Finally, Alberta Investment Management Corp grew its stake in Insulet by 57.6% in the 4th quarter. Alberta Investment Management Corp now owns 3,400 shares of the medical instruments supplier’s stock worth $888,000 after acquiring an additional 1,242 shares during the period.

Insiders Place Their Bets

In other Insulet news, EVP Eric Benjamin sold 12,394 shares of the business’s stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $280.00, for a total value of $3,470,320.00. Following the transaction, the executive vice president now owns 11,383 shares in the company, valued at $3,187,240. The trade was a 52.13 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CAO Lauren Budden sold 915 shares of the business’s stock in a transaction on Tuesday, December 10th. The stock was sold at an average price of $275.62, for a total transaction of $252,192.30. Following the completion of the transaction, the chief accounting officer now owns 5,733 shares in the company, valued at $1,580,129.46. This represents a 13.76 % decrease in their position. The disclosure for this sale can be found here. 0.47% of the stock is currently owned by company insiders.

Insulet Stock Performance

NASDAQ:PODD opened at $270.64 on Thursday. The company has a current ratio of 3.68, a quick ratio of 2.80 and a debt-to-equity ratio of 1.21. The firm has a market capitalization of $18.98 billion, a price-to-earnings ratio of 46.74, a PEG ratio of 3.62 and a beta of 1.23. The firm’s fifty day simple moving average is $273.69 and its 200 day simple moving average is $249.20. Insulet Co. has a twelve month low of $160.19 and a twelve month high of $289.46.

Insulet (NASDAQ:PODD) last posted its earnings results on Thursday, February 20th. The medical instruments supplier reported $1.15 earnings per share for the quarter, beating the consensus estimate of $1.00 by $0.15. The business had revenue of $597.50 million for the quarter, compared to analyst estimates of $582.02 million. Insulet had a net margin of 20.19% and a return on equity of 24.46%. As a group, equities research analysts expect that Insulet Co. will post 3.92 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts have commented on the stock. Wells Fargo & Company lifted their target price on shares of Insulet from $305.00 to $322.00 and gave the stock an “overweight” rating in a research note on Friday, February 21st. StockNews.com raised shares of Insulet from a “hold” rating to a “buy” rating in a research note on Monday. JPMorgan Chase & Co. lifted their target price on shares of Insulet from $280.00 to $330.00 and gave the stock an “overweight” rating in a research note on Thursday, December 12th. Raymond James reissued an “outperform” rating and set a $328.00 price objective (up from $294.00) on shares of Insulet in a research note on Friday, February 21st. Finally, Barclays boosted their price objective on shares of Insulet from $220.00 to $234.00 and gave the company an “equal weight” rating in a research note on Monday, November 11th. Three equities research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company’s stock. According to data from MarketBeat, Insulet presently has an average rating of “Moderate Buy” and an average target price of $289.06.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.